



## Joint Summit of International Bladder Cancer Group (IBCG) & the Global Society of Rare Genitourinary Tumors (GSRGT)

**DECEMBER 14<sup>th</sup>, 2024**

**Sala Convegni - HOTEL NH Milano 2 - SEGRATE [MI]**

### **DEFINING NEW ENDPOINTS AND DESIGN OF NEXT-GENERATION TRIALS OF PERIOPERATIVE THERAPIES IN MUSCLE-INVASIVE BLADDER CANCER**

half a day (13.00-17.30)

- 13.00 - 13.15 **Welcome and Introduction**  
*Andrea Necchi, Matthew D. Galsky (virtual), Ashish M. Kamat, Philippe E. Spiess*
- 13.15 - 13.25 **Fresh updates on neoadjuvant therapy trials in MIBC: local vs systemic therapy**  
*Andrea Necchi*
- 13.25 - 13.35 **Contextualizing the use of clinical response to neoadjuvant therapy in MIBC:  
framework of the available data**  
*Matthew D. Galsky (virtual)*
- 13.35 - 13.45 **The urologist's perspective: when, how and why shall we avoid radical cystectomy**  
*Sarah P. Psutka (virtual)*
- 13.45 - 13.55 **The radiologist's perspective: how can we improve the accuracy of cross sectional imaging**  
*Lawrence H. Schwartz*
- 13.55 - 14.05 **The patient perspective: a vision on a novel therapeutic journey**  
*Rick Bangs (virtual)*

14.05 - 14.15 **The radiation oncologist perspective: defining unfitnes to radical radiotherapy**  
*Jason A. Efstathiou*

14.15 - 14.35 **The regulatory perspective: European Medicines Agency**  
*Olli Tenhunen*

14.35 - 14.55 **The regulatory perspective: U.S. Food and Drug Administration**  
*Elaine Chang (virtual)*

14.55 – 15.30 *Coffee Break*

15.30 - 17.10 **Roundtable discussion and consensus development:  
using clinical complete response in modern perioperative therapy trials**

Facilitators: *Andrea Necchi, Matthew D. Galsky (virtual), Ashish M. Kamat, Philippe E. Spiess*

Discussants:

**Medical oncologists:** *Neeraj Agarwal, Petros Grivas, Sumanta K. Pal, Yohann Loriot, Shilpa Gupta, Begoña Pérez-Valderrama (virtual), Fernando Maluf, Andrea Apolo (virtual), Jonathan Rosenberg (virtual), Daniel M. Geynisman (virtual), Elizabeth Plimack (virtual), Guru P. Sonpavde (virtual), Sarmad Sadeghi*

**Urologists:** *Francesco Montorsi, Alberto Briganti, Ashish M. Kamat, Philippe E. Spiess, Maurizio Brausi, Marco Moschini, Sarah P. Psutka (virtual), Dingwei Ye (virtual), Bogdana Schmidt (virtual), Seth Lerner (virtual), Siamak Daneshmand (virtual), Peter C. Black (virtual), Savino di Stasi*

**Radiation oncologists:** *Jason A. Efstathiou, Leslie Ballas (virtual), Nick D. James (virtual)*

**Radiologists:** *Lawrence H. Schwartz, Giorgio Brembilla*

**Nuclear medicine physicians:** *Arturo Chiti*

**Pathologists:** *Hikmat Al-Ahmadie (virtual), Maurizio Colecchia, Liang Cheng (virtual), Alessia Cimadamore (virtual)*

**FDA representatives:** *Jaleh Fallah (virtual), Daniel Suzman (virtual), Sundeep Agrawal (virtual), Elaine Chang (virtual), Chana Weinstock (virtual)*

**EMA representatives:** *Francesco Pignatti, Elias Pean, Olli Tenhunen*

**Biostatisticians:** *Alexia Iasonos (virtual), Irina Ostrovnaya (virtual)*

**Patient advocates:** *Rick Bangs (virtual), Lydia E. Makaroff (virtual)*

- 15.30 - 15.40 **Presentation of the results of the IBCG virtual poll**  
*Andrea Necchi*
- 15.40 - 15.50 **Discussion**  
*Ashish M. Kamat*
- 15.50 - 16.00 **Update from RETAIN: type of relapses, treatment patterns and outcomes**  
*Daniel M. Geynisman (virtual)*
- 16.00 - 16.05 **Discussion – Facilitators**
- 16.05 - 16.15 **Update from HCRN GU16-257: type of relapses, treatment patterns and outcomes**  
*Matthew D. Galsky (virtual)*
- 16.15 – 16.20 **Discussion – Facilitators**
- 16.20 - 16.30 **Outline of the type of relapses, treatment patterns and outcomes after standard chemoradiation protocols**  
*Nick D. James (virtual)*
- 16.30 - 16.40 **Emerging data on liquid biomarkers associated with complete response to neoadjuvant therapy: ctDNA – Petros Grivas;  
utDNA – Liang Cheng (virtual)**
- 16.40 - 16.50 **Statistical considerations for the design of a randomized trial incorporating a response-based approach**  
*Alexia Iasonos (virtual) / Irina Ostrovnaya (virtual)*
- 16.50 - 17.10 **Final Roundtable Discussion and Conclusions – All Faculty**



**DECEMBER 14<sup>th</sup>, 2024**  
**SEGRATE [MI]**

**Neeraj Agarwal**

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA

**Sundeep Agrawal**

Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

**Hikmat Al-Ahmadie**

Department of Pathology and Laboratory Medicine, Genitourinary Pathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Andrea B. Apolo**

Genitourinary Malignancies Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA

**Leslie Ballas**

Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

**Rick Bangs**

Bladder Cancer Advocacy Network, Bethesda, MD, USA

**Peter C. Black**

Department of Urology Sciences at the University of British Columbia (UBC), Vancouver, Canada

**Maurizio Brausi**

Department of Urology, Cure Hesperia Hospital, Modena, Italy

**Giorgio Brembilla**

Department of Radiology, IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University, Milan, Italy

**Alberto Briganti**

Department of Urology, IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University, Milan, Italy

**Elaine Chang**

Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

**Liang Cheng**

Department of Pathology and Laboratory Medicine, Department of Surgery/Urology, Warren Alpert Medical School of Brown University, Lifespan Health, and The Legorreta Cancer Center at Brown University, Providence, RI, USA

**Arturo Chiti**

Department of Nuclear Medicine, IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University, Milan, Italy

**Alessia Cimadamore**

Institute of Pathological Anatomy, Department of Medicine (DMED), Udine University, Udine, Italy

**Maurizio Colecchia**

Department of Pathology, IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University, Milan, Italy

**Siamak Daneshmand**

Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

**Savino Di Stasi**

Operative Unit of urology, Policlinico Tor Vergata, Tor Vergata University of Rome, Italy  
Cattedra di urologia, Catholic University, "Our Lady of Good Counsel", Tirane, Albania

**Jason A. Efstathiou**

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

**Jaleh Fallah**

Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

**Matthew D. Galsky**

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

**Daniel M. Geynisman**

Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

**Petros Grivas**

University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA

**Shilpa Gupta**

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

**Alexia Iasonos**

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Nick D. James**

Institute of Cancer Research and the Royal Marsden Hospital, London, UK

**Ashish M. Kamat**

President, International Bladder Cancer Group (IBCG) Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

I N V I T E D F A C U L T Y



**DECEMBER 14<sup>th</sup>, 2024**  
**SEGRATE [MI]**

**Seth P. Lerner**

Baylor College of Medicine, Dan L Duncan Cancer Center, Houston, TX, USA

**Yohann Lorient**

Department of Cancer Medicine, INSERM U981, GustaveRoussy, UniversitéParis-Saclay, Villejuif, France

**Lydia E. Makaroff**

World Bladder Cancer Patient Coalition, Brussels, Belgium; Fight Bladder Cancer UK, Oxford, UK

**Fernando Maluf**

Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil; Hospital Beneficencia Portuguesa de São Paulo, São Paulo, SP, Brazil

**Francesco Montorsi**

Department of Urology, IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University, Milan, Italy

**Marco Moschini**

Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy

**Andrea Necchi**

Department of Medical Oncology, IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University, Milan, Italy

**Irina Ostrovnya**

Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Sumanta K. Pal**

City of Hope Comprehensive Cancer Center, Duarte, CA, USA

**Elias Pean**

European Medicines Agency, Amsterdam, Netherlands

**Begoña Pérez-Valderrama**

Hospital Universitario Virgen del Rocío, Seville, Spain

**Francesco Pignatti**

European Medicines Agency, Amsterdam, Netherlands

**Elizabeth Plimack**

Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA

**Sarah P. Psutka**

Department of Urology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA

**Jonathan E. Rosenberg**

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Sarmad Sadeghi**

MD, PhD, Associate Professor of Clinical Medicine and Urology, Norris Comprehensive Cancer Center University of Southern California

**Bogdana Schmidt**

Huntsman Cancer Institute, University of Utah, Salt Lake City Veterans Administration Medical Center, Salt Lake City, Utah, USA

**Lawrence H. Schwartz**

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Guru P. Sonpavde**

Director of Genitourinary Medical Oncology & Phase I, Clinical Research Christopher K. Glanz Chair for Bladder Cancer Research, AdventHealth Cancer Institute, Professor of Medicine, University of Central Florida, Orlando, FL, USA

**Philippe E. Spiess**

President, Global Society of Rare Genitourinary Tumors (GSRGT)

Department of GU Oncology, Department of Tumor Biology, Moffitt Cancer Center, Tampa, FL, USA; University of South Florida

**Daniel Suzman**

Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

**Olli Tenhunen**

M.D., Ph.D., Vice-chair, Oncology Working Party, European Medicines Agency  
Fimea, Finnish Medicines Agency

**Chana Weinstock**

Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

**Dingwei Ye**

Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Shanghai, People's Republic of China

I N V I T E D F A C U L T Y

**DECEMBER 14<sup>th</sup>, 2024**  
**SEGRATE [MI]**

Meeting Chairs: **Andrea Necchi, Matthew D.Galsky**

On behalf of IBCG (*International Bladder Cancer Group*):

**Ashish M. Kamat**

On behalf of GSRGT (*Global Society of Rare Genitourinary Tumors*):

**Philippe E. Spiess**

Location: **Sala Convegni, Hotel NH Milano 2**  
**Strada di Olgia Nuova - Segrate [Milan]**

Date: Saturday December 14<sup>th</sup>, 2024

Duration: half a day (13.00-17.30)

**EVENTO NON ECM**

**SEGRETERIA ORGANIZZATIVA**

EXPOPOINT - Organizzazione Congressi Eventi



Via Matteotti, 3  
22066 Mariano C.se - Co



tel. 031 748814



segreteriacongressi@expopoint.it  
www.expopoint.it